PRCT Stock Overview
A surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PROCEPT BioRobotics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$81.46 |
| 52 Week High | US$85.81 |
| 52 Week Low | US$24.83 |
| Beta | 1.0 |
| 11 Month Change | 31.66% |
| 3 Month Change | 27.08% |
| 1 Year Change | 151.11% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 94.23% |
Recent News & Updates
Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Aug 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
Aug 25
Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04Recent updates
Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Aug 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
Aug 25Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce
May 21The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Apr 05US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results
Mar 01Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt
Feb 07Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher
Dec 14Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?
Feb 27Procept Biorobotics announces $52M debt refinancing
Oct 10Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems
Sep 19Procept BioRobotics Has Resources To Ramp Up Commercialization
Sep 01Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment
May 26Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues
May 10PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target
Mar 10Shareholder Returns
| PRCT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 25.3% | 2.1% | 0.6% |
| 1Y | 151.1% | 10.2% | 22.9% |
Return vs Industry: PRCT exceeded the US Medical Equipment industry which returned 11.6% over the past year.
Return vs Market: PRCT exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| PRCT volatility | |
|---|---|
| PRCT Average Weekly Movement | 10.0% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRCT's share price has been volatile over the past 3 months.
Volatility Over Time: PRCT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 626 | Reza Zadno | www.procept-biorobotics.com |
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH.
PROCEPT BioRobotics Corporation Fundamentals Summary
| PRCT fundamental statistics | |
|---|---|
| Market cap | US$4.05b |
| Earnings (TTM) | -US$103.71m |
| Revenue (TTM) | US$176.58m |
24.0x
P/S Ratio-40.8x
P/E RatioIs PRCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRCT income statement (TTM) | |
|---|---|
| Revenue | US$176.58m |
| Cost of Revenue | US$79.93m |
| Gross Profit | US$96.65m |
| Other Expenses | US$200.35m |
| Earnings | -US$103.71m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.00 |
| Gross Margin | 54.73% |
| Net Profit Margin | -58.73% |
| Debt/Equity Ratio | 21.2% |
How did PRCT perform over the long term?
See historical performance and comparison